Concord Drugs Limited has announced a board meeting that approved increasing its authorized share capital from Rs. 11 Cr to Rs. 15.5 Cr, expanding equity shares from 1.1 crore to 1.55 crore shares of Rs. 10 each.

This change will be reflected in the Memorandum of Association, subject to shareholder approval at the upcoming Extra-Ordinary General Meeting.

The move strengthens the company's capital base, providing greater flexibility for future growth or funding needs, which is positive for shareholders as it supports business expansion opportunities.